
GeoVax Labs GOVX
$ 1.2
-6.25%
Annual report 2025
added 04-15-2026
GeoVax Labs EV - Enterprise Value 2011-2026 | GOVX
Annual EV - Enterprise Value GeoVax Labs
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 658 K | -2.13 M | -1.73 M | -26.9 M | 6.81 M | -2.58 M | 1.8 M | 5.56 M | 3.58 M | 2.46 M | 1.47 M | 5.73 T | 10.4 T | 12.8 T | 13.7 T |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.7 T | -26.9 M | 2.84 T |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | ||
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
Akari Therapeutics, Plc
AKTX
|
79.3 B | $ 5.14 | 11.87 % | $ 346 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.9 | 4.56 % | $ 9.38 B | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
43.3 B | $ 319.85 | -4.06 % | $ 41.9 B | ||
|
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Aligos Therapeutics
ALGS
|
82.6 M | $ 7.58 | 2.1 % | $ 74.9 M | ||
|
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 21.82 | 0.65 % | $ 1.02 B | ||
|
CymaBay Therapeutics
CBAY
|
3.36 B | - | - | $ 3.45 B | ||
|
Burford Capital Limited
BUR
|
3.22 B | $ 4.71 | -0.63 % | $ 766 M | ||
|
BioNTech SE
BNTX
|
-4.91 B | $ 101.59 | 2.13 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Cabaletta Bio
CABA
|
253 M | $ 3.49 | 2.69 % | $ 351 M | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 3.07 | -3.15 % | $ 5.05 M | ||
|
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
24.7 M | - | -5.16 % | $ 5.39 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
493 M | $ 1.37 | -11.94 % | $ 352 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
540 M | $ 4.28 | 0.94 % | $ 458 M | ||
|
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 24.04 | -2.2 % | $ 3.06 B | ||
|
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
629 M | $ 1.59 | 6.81 % | $ 423 M | ||
|
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B | ||
|
Checkpoint Therapeutics
CKPT
|
174 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-6.94 M | - | -16.75 % | $ 25.8 M | ||
|
AVROBIO
AVRO
|
-35.4 M | - | 1083.1 % | $ 745 M | ||
|
Clearside Biomedical
CLSD
|
122 M | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
2.07 B | $ 33.68 | -0.56 % | $ 2.24 B | ||
|
bluebird bio
BLUE
|
270 M | - | - | $ 546 M | ||
|
CNS Pharmaceuticals
CNSP
|
-2.04 M | $ 2.75 | - | $ 1.22 M |